Cholesterol drug cuts first cardiovascular events by 31% in diabetics without artery disease

A Mass General Brigham study finds the PCSK9 inhibitor evolocumab, added to standard therapy, reduces the risk of a first major cardiovascular event by 31% over ~5 years in high‑risk diabetics without diagnosed atherosclerosis, with about a 51% drop in LDL‑C. Safety was similar to placebo, suggesting earlier intensive cholesterol lowering may prevent heart attacks and strokes in patients without established artery disease; results were presented at the ACC and published in JAMA.